SCHEMBL1370451

SCHEMBL1370451

Nc1cc(CC(=O)c2cc3ccccc3sc2=O)ccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA4 P22748 1/20 0.51
CA5A P35218 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51
CA14 Q9ULX7 1/20 0.51
CA5B Q9Y2D0 1/20 0.51
F12 P00748 1/20 0.39
PIK3CA P42336 2/20 0.39
CASP3 P42574 2/20 0.38
CASP7 P55210 2/20 0.38
ALOX5 P09917 1/20 0.37
HDAC2 Q92769 3/20 0.36
HDAC1 Q13547 2/20 0.36
BCL2L1 Q07817 1/20 0.35
OPRM1 P35372 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1367470 0.87 PIK3CA (0.38) CA12CA1CA2CA4CA5A
SCHEMBL4346323 0.87 PIK3CA (0.38) CA12CA1CA2CA4CA5A
SCHEMBL1367378 0.83 CA12 (0.57) CA12CA1CA2CA4CA5A
SCHEMBL1368543 0.81 CA12 (0.47) CA12CA1CA2CA4CA5A
SCHEMBL1369341 0.78 PIK3CA (0.35) PIK3CACASP3CASP7LMNA
SCHEMBL1368749 0.77 IDO1 (0.44) PIK3CAALOX5KDM4EALDH1A1
SCHEMBL1366631 0.75 USP2 (0.56) CA12CA1CA2CA4CA5A
SCHEMBL1367584 0.75 CA12 (0.54) CA12CA1CA2CA4CA5A
SCHEMBL831421 0.75 CYP3A4 (0.41) CA12CA1CA2CA4CA5A
SCHEMBL1370632 0.71 PIK3CA (0.47) CA12CA1CA2CA4CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS CA12 4005/4885CA1 4493/4885CA2 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.